[Expression of angiogenic factors and their clinical significances in acute myeloid leukemia].
OBJECTIVE
To investigate the expression of vascular endothelial growth factor (VEGF) & basic fibroblast growth factor (bFGF) in primary acute myeloid leukemia (AML) cells, and study plasma VEGF& bFGF concentration in patients with AML and the two factors' clinical significance.


METHODS
VEGF&bFGF and their receptors mRNA expression were detected by RT-PCR; VEGF & bFGF plasma level was analyzed by ELISA.


RESULTS
In 107 AML patients, the positive mRNA expression rate of VEGF, KDR and Flt1 was 56.1%, 49.5%, and 2.8%, respectively; for bFGF and FGFR1-4, the positive rate was 21.5%, 35.5%, 9.4%, 35.5% and 23.4%, respectively. VEGF concentration in AML (154.75+/-109.98) pg/ml was significantly higher than that in AML-CR (72.05+/-23.39) pg/ml and the normal control (99.91+/-41.87) pg/ml (P< 0.05). Nevertheless, the level of bFGF had no significant difference among AML, AML-CR and the normal control. VEGF level (124.05+/-76.57) pg/ml in patients, who got complete remission (CR) after 2 cycles of chemotherapy, was remarkably lower than that (211.243+/-169.88) pg/ml in patients without CR (P< 0.05). Furthermore, the higher the concentration of VEGF & bFGF, the shorter the survival was.


CONCLUSIONS
VEGF& bFGF and their receptors mRNA in leukemic patients could be expressed to some degree,and our investigation suggested VEGF &bFGF and their receptors probably be produced by autocrine or paracrin. Abnormally high level of VEGF may be a poor factor for chemotherapy and survival in AML. The prognosis of patients with AML may be improved by treating VEGF and their receptors as therapy targets.
Wang
Yi
Y
State Key Library of Experiment Hematology,Institute of Hematology and Blood Diseases Hospital, CAMS and PUMC, Tianjin, 300020, P.R.China.
Xiao
Zhi-Jian
ZJ
Liu
Peng
P
Peng
Zhi
Z
Han
Zhong-Chao
ZC
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis* / Q000235:genetics; D006801:Humans; D007951:Leukemia, Myeloid / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D017468:Receptors, Fibroblast Growth Factor / Q000096:biosynthesis / Q000235:genetics; D015996:Survival Rate; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis* / Q000235:genetics; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000096:biosynthesis / Q000235:genetics; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000096:biosynthesis / Q000235:genetics
D012333:RNA, Messenger; D017468:Receptors, Fibroblast Growth Factor; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2